Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate

The Maryland-based late-stage biotechnology company in April said it identified the candidate, NVX-CoV2373, with which it planned to use its Matrix-M adjuvant to enhance immune responses.

Adjuvants are mainly used to make vaccines induce a strong immune response, including through the greater production of antibodies, and provide longer-lasting protection against viral and bacterial infection.

Novavax said it expects preliminary immunogenicity and safety results from the trial in July.

The announcement comes as drugmakers pause clinical trials for other ailments and race to find an antidote for COVID-19, the illness caused by the novel coronavirus which has infected more than 5.3 million people worldwide and killed over 343,000.

Novavax said, upon successful completion of Phase 1, the Phase 2 portion of the trial will be conducted in several countries, including the United States.

The Phase 2 trial will assess immunity, safety and COVID-19 disease reduction in a broader age range, Novavax said.

Next Post

Cuanto cuesta un transplante de cabello en Estados Unidos?

Tue May 26 , 2020
Cuanto cuesta un transplante de cabello en Estados Unidos? Cuanto cuesta un transplante de cabello en Estados Unidos?. El costo de un trasplante de cabello es muy variable y generalmente oscila entre $4,000 y $15,000. Estos costos son a menudo todos de su bolsillo. La mayoría de las compañías de seguros […]

You May Like